A. Crandon - Concepedia

Author

A. Crandon

Also Known As

A CRANDON, A J Crandon, A. Crandon, A. J. Crandon, A.J. CRANDON, A.J. Crandon, Alex J. Crandon, Alexander J Crandon, Alexander J. Crandon, Crandon A

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Royal Brisbane and Women's Hospital Royal Women's Hospital The University of Queensland Mater Health Services Mater Research

About

A. Crandon is an author at Royal Brisbane and Women's Hospital specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	383
2	Health Sciences	2	2	72
3	Public Health	1	1	26
4	Cell Biology	1	1	39
5	Cellular Physiology	1	1	39

A. Crandon

Publications

623

Citations

H-Index

Page 1

	Year	Citations
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer Brittney S. Harrington, Yaowu He, Claire M. Davies, British Journal of Cancer	2016	80
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance Yaowu He, Andy Wu, Brittney S. Harrington, Oncogene	2015	71
Peritoneal cytology: impact on disease-free survival in clinical stage I endometrioid adenocarcinoma of the uterus Andreas Obermair, Magda Geramou, Lee Tripcony, Cancer Letters Clinical StageGynecological SurgerySurgical PathologyGynecologyPathology	2001	64
Local Recurrence in High-Risk Node-Negative Stage I Endometrial Carcinoma Treated with Postoperative Vaginal Vault Brachytherapy T.Y. Ng, Lewis Perrin, James Nicklin, Gynecologic Oncology Gynecological SurgeryMedicineHigh-risk Node-negative StageBrachytherapyGynecology	2000	62
Efficacy of routine follow-up in patients with recurrent uterine cancer Colin Smith, M. Heeren, James Nicklin, Gynecologic Oncology Recurrent Uterine CancerMedicineCancer RecurrenceCancer ManagementGynecology	2007	55
L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution Thu H.M. Nguyen, Patricia E. Carreira, Francisco J. Sánchez‐Luque, Cell Reports	2018	55
EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface Mark N. Adams, Brittney S. Harrington, Yaowu He, Oncogene Membrane-spanning Procancer Cdcp1Palmitoylation-dependent DegradationCell SurfaceProtein DegradationCell Proliferation	2014	39
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses Eun Young Kang, Dane Cheasley, Cécile Le Page, Modern Pathology Tumor HeterogeneityMedicineGynecologyPathologyTp53 Mutation Status	2020	38
Postoperative Vaginal Vault Brachytherapy for Node-Negative Stage II (Occult) Endometrial Carcinoma T.Y. Ng, James Nicklin, Lewis Perrin, Gynecologic Oncology Gynecological SurgeryMedicineNode-negative Stage IiBrachytherapyGynecology	2001	35
Early-stage vaginal carcinoma - an analysis of 70 patients Geoff Otton, James Nicklin, G. Dickie, International Journal of Gynecological Cancer	2004	34

Page 1